Medipal HoldingsMAHLY +5.92%78 Gross Margin % is 6.84% as of Mar. 2026, which is 2% below its 10-year median of 6.95. GuruFocus rates MAHLY with a GF Score™ of 78/100 and a GF Value™ of $16.44 (Fairly Valued). The stock has 1 warning sign investors should review. Among 116 Medical Distribution companies, Medipal Holdings ranks worse than 90.52% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Medipal Holdings had a gross margin of 6.84% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Medipal Holdings Gross Margin % Related Terms
Medipal Holdings Gross Margin % Historical Data
* Premium members only.
The historical data trend for Medipal Holdings's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Medipal Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medipal Holdings Gross Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Medipal Holdings's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Medipal Holdings's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Medipal Holdings (MAHLY) has a Gross Margin % of 6.84% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Medipal Holdings and its competitors. This is near median its historical median of 6.95. Over the past decade, Medipal Holdings' Gross Margin % has ranged from 6.61 to 7.31. According to the industry distribution chart, Medipal Holdings ranks #105 out of 116 companies in the Medical Distribution industry, placing it in the top 90.5%.
Is Medipal Holdings' Gross Margin % too high?
Medipal Holdings' current Gross Margin % of 6.84% is near median its 10-year median of 6.95. Over the past 10 years, this metric has ranged from a low of 6.61 to a high of 7.31. The Medical Distribution industry median Gross Margin % is 14.90. Medipal Holdings' value of 6.84% is 54.1% below this industry median. Based on the distribution chart, Medipal Holdings ranks #105 out of 116 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Medipal Holdings has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medipal Holdings' Gross Margin % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Medipal Holdings ranks #105 out of 116 companies for Gross Margin %. This places Medipal Holdings in the lower half of its industry. The industry median Gross Margin % is 14.90. Medipal Holdings' value of 6.84% is 54.1% below this benchmark. Historically, Medipal Holdings' own Gross Margin % has ranged from 6.61 to 7.31 over the past decade. While the company's 10-year median is 6.95 vs. the industry median of 14.90, Medipal Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Distribution company?
The median Gross Margin % among Medical Distribution companies is 14.90, based on 116 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medipal Holdings's current Gross Margin % of 6.84% is 54.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Medipal Holdings and its competitors. For the Medical Distribution industry, the median Gross Margin % is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medipal Holdings's current Gross Margin % is 6.84%, which is near median its own 10-year median of 6.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medipal Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medipal Holdings (MAHLY) is currently considered Fairly Valued. The stock's GF Value™ is $16.44, compared to a current price of $16.28 — trading 1% below its estimated fair value. The current Gross Margin % is 6.84%, which is near median its 10-year median of 6.95 and 54.1% below the Medical Distribution industry median of 14.90. Medipal Holdings' overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Medipal Holdings (MAHLY), the current Gross Margin % is 6.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medipal Holdings (MAHLY) Overvalued in 2026?
Based on GuruFocus' analysis, Medipal Holdings stock appears to be undervalued.
The current stock price of $16.28 is trading 1% below its estimated GF Value™ of $16.44.
GuruFocus considers Medipal Holdings to be Fairly Valued.
Key valuation signals for MAHLY:
Gross Margin %: 6.84% (near median its 10-year median of 6.95)
GF Value™: $16.44 vs. price of $16.28 (1% below fair value)
Industry Position: 54.1% below the Medical Distribution median (#105 of 116)
No single metric tells the full story. See the MAHLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medipal Holdings Corp is engaged in the wholesale distribution of pharmaceuticals, cosmetics, daily necessities, and related products. The company operates through three reportable segments: Wholesale business of medical drugs; Cosmetics, Daily Necessities and OTC Pharmaceuticals Wholesale Business; and Wholesale of animal medicines and food processing ingredients. The Wholesale business of medical drugs segment targets hospitals, clinics, and dispensing pharmacies; the Cosmetics and OTC segment serves drug stores, home centers, convenience stores, and supermarkets; while the Wholesale of animal medicines and food processing ingredients segment supplies veterinary clinics, livestock and fisheries businesses, and food manufacturers.
78GF Score
Get the complete analysis for MAHLY
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MAHLY has been successfully added to your 
